open access

Vol 45, No 5 (2011)
ARTYKUŁ ORYGINALNY
Submitted: 2010-10-02
Get Citation

The double immunostaining of CD133 and Ki-67 favours a significant co-localization pattern in fibroblastic subtype of meningiomas

Baki S. Albayrak, Ozgur Ismailoglu, Gamze Tanriover, Eralp N. Cetinalp, Necdet Demir
DOI: 10.1016/S0028-3843(14)60315-7
·
Neurol Neurochir Pol 2011;45(5):467-473.

open access

Vol 45, No 5 (2011)
ARTYKUŁ ORYGINALNY
Submitted: 2010-10-02

Abstract

Background and purpose

A unique molecular and/or cellular marker for meningiomas, the most common intracranial tumours, has not been identified yet.

Material and methods

We investigated the co-localization fraction of CD133/Ki-67 in meningioma tissue array slide composed of 80 meningioma tissue samples of various histological variants. CD133 – a cell membrane stem cell marker – was previously proved to be associated with the initiation and progression of intracerebral gliomas and medulloblastomas.

Results

Immunohistochemical co-localization of CD133/Ki-67 was significantly higher in fibroblastic variant than in meningothelial and transitional subtypes. However, since there were only 3 atypical and 1 malignant meningioma spots in the tumour tissue array slide, it is difficult to draw a firm conclusion regarding the actual co-localization percentage and persistence of CD133/Ki-67 in atypical and malignant meningiomas.

Conclusions

Far higher co-staining percentage of CD133/Ki-67 in fibroblastic meningioma samples compared to meningothelial subtype, a histological meningioma variant, architectonically resembling the non-neoplastic meningeal cells, gave us the impression that CD133 may play a role in the formation and progression of fibroblastic meningioma variants. The persistency and the validity of this finding need to be verified by further histopathological and molecular research in order to clarify the possible role of CD133 in meningiogenesis.

Abstract

Background and purpose

A unique molecular and/or cellular marker for meningiomas, the most common intracranial tumours, has not been identified yet.

Material and methods

We investigated the co-localization fraction of CD133/Ki-67 in meningioma tissue array slide composed of 80 meningioma tissue samples of various histological variants. CD133 – a cell membrane stem cell marker – was previously proved to be associated with the initiation and progression of intracerebral gliomas and medulloblastomas.

Results

Immunohistochemical co-localization of CD133/Ki-67 was significantly higher in fibroblastic variant than in meningothelial and transitional subtypes. However, since there were only 3 atypical and 1 malignant meningioma spots in the tumour tissue array slide, it is difficult to draw a firm conclusion regarding the actual co-localization percentage and persistence of CD133/Ki-67 in atypical and malignant meningiomas.

Conclusions

Far higher co-staining percentage of CD133/Ki-67 in fibroblastic meningioma samples compared to meningothelial subtype, a histological meningioma variant, architectonically resembling the non-neoplastic meningeal cells, gave us the impression that CD133 may play a role in the formation and progression of fibroblastic meningioma variants. The persistency and the validity of this finding need to be verified by further histopathological and molecular research in order to clarify the possible role of CD133 in meningiogenesis.

Get Citation

Keywords

meningioma, fibroblastic, CD133, Ki-67, tissue array, co-localization

About this article
Title

The double immunostaining of CD133 and Ki-67 favours a significant co-localization pattern in fibroblastic subtype of meningiomas

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 45, No 5 (2011)

Pages

467-473

DOI

10.1016/S0028-3843(14)60315-7

Bibliographic record

Neurol Neurochir Pol 2011;45(5):467-473.

Keywords

meningioma
fibroblastic
CD133
Ki-67
tissue array
co-localization

Authors

Baki S. Albayrak
Ozgur Ismailoglu
Gamze Tanriover
Eralp N. Cetinalp
Necdet Demir

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl